نتایج جستجو برای: lysosomal storage diseases

تعداد نتایج: 1035749  

Journal: :The Journal of biological chemistry 2012
Miao Xu Ke Liu Manju Swaroop Forbes D Porter Rohini Sidhu Sally Firnkes Daniel S Ory Juan J Marugan Jingbo Xiao Noel Southall William J Pavan Cristin Davidson Steven U Walkley Alan T Remaley Ulrich Baxa Wei Sun John C McKew Christopher P Austin Wei Zheng

Niemann-Pick disease type C (NPC) and Wolman disease are two members of a family of storage disorders caused by mutations of genes encoding lysosomal proteins. Deficiency in function of either the NPC1 or NPC2 protein in NPC disease or lysosomal acid lipase in Wolman disease results in defective cellular cholesterol trafficking. Lysosomal accumulation of cholesterol and enlarged lysosomes are s...

Journal: :Biochimica et biophysica acta 2007
David E Sleat Haiyan Zheng Peter Lobel

Glycoproteins containing the mannose 6-phosphate (Man-6-P) modification represent a class of proteins of considerable biomedical importance. They include over sixty different soluble lysosomal hydrolases and accessory proteins, deficiencies of which result in over forty different known human genetic diseases. In addition, there are patients with lysosomal storage diseases of unknown etiology an...

Journal: :iranian journal of child neurology 0
mohammad ghofrani

how to cite this article: ghofrani m. lysosomal storage disease. iran j child neurol autumn 2012; 6:4 (suppl. 1):1-2.   for reading more pls see pdf

عمادی, عاطفه , فکری, کیاوش , نوربخش, محمد کاظم , نکویی, افسانه , هاشمی دهکردی, الهام ,

Gangliosidosis GM1, is a lipid storage disorder due to deficiency of the lysosomal enzyme &beta-galactosidase. This deficiency leads to lysosomal accumulation of gangliosidosis GM1 to be, which contributes to swelling, cell damage and dysfunction of the organs. Gangliosidosis GM1a rare neurodegenerative disorder. Mongolian spots are significant clinical sign in some of the metabolic diseases, s...

Journal: :Molecular pharmaceutics 2016
Jeff Rappaport Rachel L Manthe Melani Solomon Carmen Garnacho Silvia Muro

Many cellular activities and pharmaceutical interventions involve endocytosis and delivery to lysosomes for processing. Hence, lysosomal processing defects can cause cell and tissue damage, as in lysosomal storage diseases (LSDs) characterized by lysosomal accumulation of undegraded materials. This storage causes endocytic and trafficking alterations, which exacerbate disease and hinder treatme...

2016
Russell D. Berg Steven Levitte Mary P. O’Sullivan Seónadh M. O’Leary C.J. Cambier James Cameron Kevin K. Takaki Cecilia B. Moens David M. Tobin Joseph Keane Lalita Ramakrishnan

A zebrafish genetic screen for determinants of susceptibility to Mycobacterium marinum identified a hypersusceptible mutant deficient in lysosomal cysteine cathepsins that manifests hallmarks of human lysosomal storage diseases. Under homeostatic conditions, mutant macrophages accumulate undigested lysosomal material, which disrupts endocytic recycling and impairs their migration to, and thus e...

2011
Diego L. Medina Alessandro Fraldi Valentina Bouche Fabio Annunziata Gelsomina Mansueto Carmine Spampanato Claudia Puri Antonella Pignata Jose A. Martina Marco Sardiello Michela Palmieri Roman Polishchuk Rosa Puertollano Andrea Ballabio

Lysosomes are cellular organelles primarily involved in degradation and recycling processes. During lysosomal exocytosis, a Ca²⁺-regulated process, lysosomes are docked to the cell surface and fuse with the plasma membrane (PM), emptying their content outside the cell. This process has an important role in secretion and PM repair. Here we show that the transcription factor EB (TFEB) regulates l...

Journal: :Journal of child neurology 1996
A Prasad E M Kaye J Alroy

In this report, we have summarized our 9-year experience of over 100 proven cases of lysosomal storage disease using electron microscopic evaluation of skin biopsies as a screening tool. The skin biopsy was very specific in establishing the diagnosis in only two disorders, namely neuronal ceroid lipofuscinosis and mucolipidosis IV. Although the biopsy was not diagnostic in other categories of s...

Journal: :Blood 1991
Joel Charrow

Gaucher disease is the most common lysosomal storage disease, and the first lysosomal storage disease for which a specific therapy has been developed. Enzyme replacement therapy, with glucocerebrosidase purified from human placentae, was introduced in 1991. Recombinant human glucocerebrosidase, produced by Chinese hamster ovary cells in tissue culture, became available in 1994 and has replaced ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید